The opportunity

South African commercial print is not one market in decline. It is two markets moving in opposite directions, and the mid-market corporate buyer is stranded between them.

Long-run lithographic work, the traditional core of the industry, continues to contract as catalogue, directory and mass-mail volumes fall. Short-run digital production, wide-format signage and point-of-sale display are growing, driven by campaign fragmentation, shorter brand cycles and the proliferation of retail and branch touchpoints. The industry statistics that describe “print in decline” aggregate these two movements and obscure both.

The corporate mid-market buyer sits awkwardly across this divide. A regional bank, a healthcare group, a franchised retailer or an insurer runs dozens to hundreds of physical touchpoints, each requiring brand-compliant collateral in small quantities, at short notice, refreshed several times a year. Legacy litho houses cannot serve them economically below minimum run sizes. Retail copy chains can serve the quantity but cannot govern the brand. National print-management bureaux govern the brand competently but own no production, so they broker rather than control turnaround and margin.

The proposition

Midrand Print Company is positioned deliberately in that gap: a single production facility in Midrand, Gauteng, owning digital sheet-fed colour, wide-format roll and UV flatbed rigid production alongside finishing, kitting and fulfilment, wrapped in a web-to-print platform that gives corporate clients governed, self-service ordering against locked brand templates. The commercial model is to convert transactional print buyers into contracted managed collateral programmes, annual agreements covering template management, ordering, production, storage and distribution across a client’s entire branch or outlet network.

Financial summary

The plan reaches R67.9 million of revenue in FY2031 from four production lines, having traded for nine months in FY2027. Gross margin stabilises at 46%, and EBITDA margin expands from negative in the ramp year to 20.9% as fixed costs are absorbed. The first profitable month is month 30; the first profitable financial year is FY2030.

Table 1: Summary financial performance, base case

Net debt / EBITDA and debt service cover are not meaningful in FY2027 because EBITDA is negative.

The funding requirement

R29.0 million is required at financial close: R12.5 million of investor equity, R3.0 million of founder equity, an R11.0 million asset finance facility secured on production plant and a R2.5 million term loan. A further R22.7 million of funding is committed across the plan period, a milestone-contingent investor equity tranche of R6.5 million, R8.7 million of expansion asset finance and a R7.5 million revolving working-capital facility. Total committed funding is R51.7 million, of which 42.6% is equity.

Returns

On an exit at 5.0 times FY2031 EBITDA at 31 December 2031, the investor realises R41.1m on R19.0m invested, a money multiple of 2.16x and an equity IRR of 17.9%. A discounted cash flow at a 15.7% weighted average cost of capital values the enterprise at R37.6m.

The three findings that matter most

An investment committee reading only this page should take away three things, and none of them is the headline IRR.

Recommendation

The proposition is fundable and the business is viable, but it is not a generalist private equity asset at the price implied by a 5.0 times exit. As Section 22 sets out, the returns profile and the capital structure suit an owner-operator consortium, a strategic or trade investor with existing corporate relationships to feed the plant, or a patient-capital or enterprise-development mandate, considerably better than they suit a fund underwriting to a 20% or higher hurdle.